ArticleThe mental health clinician2016
Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: A narrative literature review.
Article in The mental health clinician, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 116 citations in OpenAlex.
- Evaluation of the efficacy and safety of different doses of daily paroxetine in patients with lifelong premature ejaculation: a prospective randomized crossover study.International urology and nephrology · 2026Trial
- Effect of l-arginine compared to placebo on sexual function in women with major depressive disorder: a randomized controlled trial.BMC psychiatry · 2024Trial
- The effect of drug holidays on sexual dysfunction in men treated with selective serotonin reuptake inhibitors (SSRIs) other than fluoxetine: an 8-week open-label randomized clinical trial.BMC psychiatry · 2024Trial
- "It's taken away the most fundamental things about being human": the lived experience and impact of post-SSRI sexual dysfunction.International journal of qualitative studies on health and well-being · 2026Article
- Large-scale analysis demonstrates the influence of CYP2C19 genotype on specific SSRI side effects.The pharmacogenomics journal · 2026Article
- When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.Fundamental & clinical pharmacology · 2026Review
- Neurokinin receptor antagonists for vasomotor symptoms: from KNDy neurons to clinical translation.Nature reviews. Endocrinology · 2026Review
- Vagus nerve-dependent antidepressant effects of ineupatorolide B via gut microbiota modulation in a mouse model of depression.Translational psychiatry · 2026Article
- Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review.Archives of medical science : AMS · 2026Review
- Uterotropic response to the antidepressant fluoxetine (Prozac) is dependent on a functional serotonin transporter and circulating serotonin.Scientific reports · 2025Article
- Addressing Factors that Impact Sexual Well-Being and Intimacy in IBD Patients.Current gastroenterology reports · 2025Review
- Article
- Citalopram-induced decrease of CLOCK-ir and BMAL1-ir kisspeptin neurons in the anteroventral periventricular nucleus of adult male mice.IBRO neuroscience reports · 2025Article
- Systemic Consequences of Inflammatory Bowel Disease Beyond Immune-Mediated Manifestations.Journal of clinical medicine · 2025Review
- Unraveling the Cycle: A Scoping Review Exploring the Impact of Antidepressants on the Female Reproductive Cycle.Cureus · 2025Review
- Insomnia and Benzodiazepine Use as Risk Factors for Erectile Dysfunction: Clinical Evidence and In Silico Analysis of Physicochemical Properties.Journal of clinical medicine · 2025Article
- Review
- British Society for Sexual Medicine (BSSM) Position Statement on Premature Ejaculation.The world journal of men's health · 2025Review
- Depression, selective serotonin reuptake inhibitors, and sexual wellbeing in assigned females: exploring the moderating role of sexual flexibility.The journal of sexual medicine · 2025Article
- Five-Year Trends in SSRI Consumption: A Precision Medicine Approach to Comparative Analysis Between Serbia and European Countries.Healthcare (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sexual dysfunction is an underdiscussed adverse effect to selective serotonin reuptake inhibitors (SSRIs) and may increase the risk for discontinuation and nonadherence to antidepressant pharmacotherapy. Given the prevalence of depression, health care providers should educate patients about SSRI-associated sexual dysfunction in order to promote patient awareness and medication adherence. This study evaluated primary literature from 1997 to 2015 to identify SSRI-related sexual side effects, therapeutic alternatives, and treatment strategies. The results indicate that paroxetine is associated with the greatest rate of sexual dysfunction among the SSRIs. Potential alternatives to SSRI treatment include bupropion, mirtazapine, vilazodone, vortioxetine, and serotonin-norepinephrine reuptake inhibitors. In the event that a subject responds solely to SSRIs but experiences unwanted sexual side effects, bupropion may be added as an adjunctive medication. Some limited evidence also suggests that saffron may reduce some aspects of sexual dysfunction, excluding ability to reach orgasm.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.